Understanding how EML4-ALK protein clusters affect lung cancer growth
Dissecting the role and mechanism of EML4-ALK condensates in oncogenic signaling and tumor growth
This study is looking at how certain protein clusters in lung cancer might help tumors grow and resist treatment, with the goal of finding new ways to improve care and outcomes for people with non-small cell lung cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11051172 on NIH RePORTER |
What this research studies
This research investigates the role of EML4-ALK protein clusters in lung cancer, particularly focusing on non-small cell lung cancer (NSCLC). The study aims to uncover new mechanisms of oncogenic signaling by examining how these protein clusters, which lack lipid membranes, contribute to tumor growth and drug resistance. By employing a multidisciplinary approach, the researchers hope to identify innovative therapeutic strategies that could enhance patient survival rates. Patients may benefit from insights that could lead to more effective treatments for lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with ALK gene rearrangements.
Not a fit: Patients with lung cancer types that do not involve ALK gene rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and increased survival rates for lung cancer patients.
How similar studies have performed: Other research has shown promise in targeting oncogenic signaling pathways in lung cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Bivona, Trever G — University of California, San Francisco
- Study coordinator: Bivona, Trever G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.